Welcome to our dedicated page for Q/C Technologies SEC filings (Ticker: QCLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Q/C Technologies, Inc. (QCLS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents give detailed insight into how Q/C describes its quantum-class, high-performance computing infrastructure business, its licensing agreement with LightSolver for quantum-inspired laser-based processing units, and its focus on applications in the crypto and blockchain domain.
Through Q/C’s Forms 10-K and 10-Q (when filed), investors can review management’s discussion of operations, risk factors, and financial statements related to its quantum-class photonic computing initiatives and related activities. The company’s Current Reports on Form 8-K disclose material events such as private placements of preferred stock and warrants, amendments to transaction documents, consulting agreements, equity incentive plan changes, and stockholder approvals for reverse stock split authorization and share issuance proposals.
Proxy statements on Schedule 14A outline matters submitted to stockholders, including proposals tied to the issuance of common stock underlying preferred stock and warrants, increases in shares available under the 2021 Equity Incentive Plan, and other governance items. Filings such as Form 12b-25 (Notification of Late Filing) explain any reported delays in submitting periodic reports and the company’s stated plans to file within allowed extension periods.
On Stock Titan, these filings are supplemented with AI-powered summaries that aim to clarify key points from lengthy documents, such as the implications of preferred stock terms, voting rights, equity plan amendments, and reverse stock split proposals. Users can also monitor ownership and compensation-related disclosures contained in proxy materials and other filings, as well as any reported unregistered sales of equity securities and warrant issuances. Real-time updates from EDGAR combined with AI explanations help readers navigate Q/C Technologies’ regulatory history and understand the structural aspects of its quantum-class computing business as presented in its official filings.
Q/C Technologies, Inc. director Chelsea Sierra Voss received an employee stock option grant covering 50,000 shares of common stock. The options have a $5.00 per share exercise price and expire on April 13, 2036. Following this grant, she holds options for 50,000 shares directly. The options may expire earlier if she stops being employed by or providing services to the company.
Q/C Technologies, Inc. director Stephen Friscia received a grant of employee stock options covering 50,000 shares of common stock. The options have an exercise price of $5.00 per share and expire on April 13, 2036. All 50,000 options were held directly after the grant and are subject to expiration if he stops serving the company.
Q/C Technologies director Billy Joe White received a grant of employee stock options for 50,000 shares of Common Stock. The options have a conversion or exercise price of $5.00 per share, were granted on April 13, 2026, and expire on April 13, 2036. Following this award, he holds 50,000 derivative securities directly, which are subject to expiration if he stops being employed by or providing services to the company.
Q/C Technologies, Inc. reported that Chief Medical Officer Mitchell Glass received a grant of employee stock options on common stock. The award covers 50,000 options, each giving the right to buy one share of common stock at an exercise price of $5.00 per share.
These options were granted on April 13, 2026 and expire on April 13, 2036. Following this grant, Glass holds 50,000 stock options directly. The options may expire earlier if he ceases to be employed by or provide services to the company.
Q/C Technologies, Inc. reported that Executive Chairman Joshua Silverman received new equity awards. He was granted employee stock options for 100,000 shares of common stock at an exercise price of $5.00 per share, expiring on April 13, 2036, and will hold 50,000 options after this grant.
He was also awarded 162,162 shares of common stock in the form of Restricted Stock Units issued under an executive compensation agreement dated April 13, 2026. The RSUs vested immediately upon grant, bringing his direct common stock holdings to 262,191 shares.
Q/C TECHNOLOGIES, INC. director Bruce Bernstein received an award of employee stock options covering 50,000 shares of common stock on April 13, 2026. The options have an exercise price of $5.00 per share and were granted at a price of $0.00 per option.
The options are exercisable into 50,000 shares of common stock and expire on April 13, 2036. According to the filing, the options are subject to expiration if Bernstein ceases to be employed by, or to provide services to, the company.
Q/C Technologies, Inc. reports its annual results and details a major strategic shift from pharmaceuticals to laser-based computing for blockchain, DePin Token networks, and AI workloads. The company is building the qc-LPU100 photonic processor under an exclusive global license with LightSolver and acquired LPU Holdings LLC to anchor this business.
Legacy drug programs Isomyosamine and Supera-CBD remain a separate segment under strategic review for possible divestiture or partnerships. Q/C Technologies highlights substantial risks: persistent operating losses, need for significant new capital, dependence on its LightSolver license, extremely volatile crypto markets, and complex global regulation across crypto, hardware, AI, export controls, and FDA oversight.
Q/C Technologies, Inc. (formerly TNF Pharmaceuticals, Inc.) filed a Form 12b-25 notifying the SEC it cannot timely file its Annual Report on Form 10-K for the year ended December 31, 2025 because it needs additional time to complete and finalize the required financial statements. The company states it currently anticipates filing the Form 10-K on or before the fifteenth calendar day following the prescribed due date. The notice is signed by Joshua Silverman, Executive Chairman, dated March 31, 2026.
Q/C Technologies, Inc. reported that its Audit Committee dismissed Stephano Slack LLC as its independent registered public accounting firm on March 9, 2026, and appointed Grassi & Co., CPAs, P.C. as the new auditor for the year ended December 31, 2025.
The prior auditor’s reports for 2023 and 2024 contained a going concern paragraph noting net loss and negative operating cash flows for 2024 that raised substantial doubt about the Company’s ability to continue as a going concern, with no related adjustments recorded. The Company states there were no disagreements or reportable events with Stephano Slack, and it has obtained a letter from the former auditor addressed to the SEC agreeing with these disclosures.
Q/C Technologies, Inc. has filed a shelf registration statement on Form S-3 to offer and sell, from time to time, up to $100,000,000 of common stock, preferred stock, debt securities, warrants, subscription rights, and units.
The company has shifted its strategy from developing Isomyosamine and Supera-CBD therapeutics to building energy‑efficient blockchain and cryptocurrency infrastructure using laser-based computing under an exclusive global license with LightSolver. The filing notes going concern risks, potential future equity dilution, Nasdaq listing compliance risks, and a high level of investment risk.